0.637
0.06 (10.11%)
| Penutupan Terdahulu | 0.579 |
| Buka | 0.600 |
| Jumlah Dagangan | 1,525,832 |
| Purata Dagangan (3B) | 1,182,090 |
| Modal Pasaran | 1,994,977,664 |
| Harga / Jualan (P/S) | 1.71 |
| Harga / Buku (P/B) | 97.15 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 May 2025 |
| Margin Operasi (TTM) | -17,994.78% |
| EPS Cair (TTM) | -0.590 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.91% |
| Nisbah Semasa (MRQ) | 10.96 |
| Aliran Tunai Operasi (OCF TTM) | -121.30 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -114.20 M |
| Pulangan Atas Aset (ROA TTM) | -28.29% |
| Pulangan Atas Ekuiti (ROE TTM) | -45.28% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | ProKidney Corp. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 2.10 |
|
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 30.05% |
| % Dimiliki oleh Institusi | 41.66% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Brown University | 31 Mar 2025 | 1,000,000 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 9.00 (Citigroup, 1,312.43%) | Beli |
| Median | 5.00 (684.68%) | |
| Rendah | 1.00 (B of A Securities, 56.94%) | Jual |
| Purata | 5.00 (684.68%) | |
| Jumlah | 1 Beli, 1 Jual | |
| Harga Purata @ Panggilan | 2.47 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citigroup | 09 Jul 2025 | 9.00 (1,312.43%) | Beli | 4.34 |
| B of A Securities | 30 Jun 2025 | 1.00 (56.94%) | Jual | 0.592 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| WEBER DARIN J. | - | 3.73 | -103,480 | -385,980 |
| Jumlah Keseluruhan Kuantiti Bersih | -103,480 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -385,980 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 3.73 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| WEBER DARIN J. | Pegawai | 08 Jul 2025 | Jual automatik (-) | 103,480 | 3.73 | 385,980 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 09 Jul 2025 | Pengumuman | ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference |
| 08 Jul 2025 | Pengumuman | ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes |
| 01 Jul 2025 | Pengumuman | ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware |
| 12 May 2025 | Pengumuman | ProKidney Reports First Quarter 2025 Financial Results and Business Highlights |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |